Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Realty, IT stocks find favour
Fri, 1 Jul 11:30 am

Indian stock market indices have shed some of the early morning gains on account of profit booking. realty and IT stocks are trading in the green while Auto and consumer durables are on the losing end.

The BSE-Sensex is up by 43 points while NSE-Nifty is trading 5 points above previous closing. BSE Midcap and BSE Small cap indices are up by 0.8% and 0.9% respectively. The rupee is trading at 44.60 to the US dollar.

IT stocks are trading firm led by Crane Software and Mastek. As per a leading daily, the Income Tax Department has initiated scrutiny on Tata Consultancy Services for claiming tax benefits for onshore services. It may be noted here that onshore software services make up 45% of TCS's total revenues. Onshore development refers to the practice of IT companies sending their employees to work at the client's place abroad including the US and Europe.

The IT department has recently revised its argument that software services provided by Indian companies should be treated as export of manpower and not software. The IT department argues that since professionals are under the control and the supervision of the company abroad, the contract actually amounts to export of manpower. Many software companies book their earnings from onshore work in their units located in the Software Technology Parks of India to avail tax benefits.

Pharma stocks are trading mixed with Elder Pharma and Biocon Limited trading firm while Panacea Biotech and Ranbaxy Laboratories are trading weak. As per a leading financial daily, Global pharma giant Pfizer Inc has sued Aurobindo Pharma over the generic version of Lipitor. It may be noted that Lipitor, is one of the best selling medications in the American market. The annual sales for the drug in the country stand at approximately US$ 7 bn. According to Pfizer, it has exclusive production right of Lipitor until 2017 as per patents covering the blockbuster drug's brand name. Pfizer has now requested the court to refrain Aurobindo from manufacturing and marketing the drug before January 8, 2017. This is the date of expiration of the patent, including the period of exclusivity granted to Lipitor. It is reported that Aurobindo may opt for out-of-court settlement with Pfizer. It may be recalled that earlier this year, Pfizer had filed a patent infringement suit against Dr Reddy's Laboratories over the same drug.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Realty, IT stocks find favour". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.